CORAL SPRINGS, Florida, August 28, 2013 /PRNewswire/ --
FinancialNewsMedia.com issues news updates for today's leading healthcare companies: Bio-Solutions Corp. (OTCQB: BISU), Catalyst Pharmaceutical Partners, Inc. (NASDAQ: CPRX), MannKind Corporation (NASDAQ: MNKD), Amgen (NASDAQ: AMGN) and Accuray Incorporated (NASDAQ: ARAY).
Bio-Solutions Corp. (BISU): Bio-Solutions Corp. Announces National Direct Response Marketing Campaign for Type2Defense™. Bio-Solutions today announces a major step in their company's expansion process across the USA and commitment to growth across America; as management celebrates the national roll-out of a Direct Response Infomercial and Marketing Campaign for its flagship product Type2Defense™. Type2Defense™ is a new dietary supplement that has been developed to help support healthy blood glucose levels in health-conscious individuals and those diagnosed with Type 2 Diabetes. The Product's goal is to provide a safe and natural supplement that will assist in the stabilization of healthy glucose levels along with providing strong antioxidants.
Bill Gallagher, CEO of Bio-Solutions Corp, said, "We are very excited to be launching our unique product via direct response television in the USA, and especially feeling confident that partnering with GVP Digital Media will give us the edge for a successful campaign." Compared to other consumer groups, diabetics are 1.6 times more likely to use alternative medicine either exclusively or as a complement to traditional treatment. GVP Digital Media, a leader in Direct Response, will begin to actively market Type2Defense through their media contacts and network of brokers, sales consultants and agents. GVP has already started test marketing Type2Defense in a National radio campaign.
To read the entire press release, please go to http://fnmprofiles.com/profiles-bisu.php
Tuesday of this week, Bio-Solutions announced that the Company has initiated a campaign on Lockerdome.com to help raise money for the benefit of Juvenile Diabetes. Lockerdome.com is the premier destination on the internet for both professional and amateur athletes. Monthly traffic to Lockerdome.com is in excess of 14 million visitors per month and Bio-Solutions is confident that it can reach athletes who have diabetes through Lockerdome.com and help them reach their training potential by using the company's product, Type 2 Defense. The Bio-Solutions Corp. page on Lockerdome.com will allow young athletes with diabetes to interact with pro athletes with diabetes. This one on one interaction with the pros will show young diabetics that diabetes is not an obstacle to achieving greatness. The pro ranks are full of star athletes who have made it to the top without letting diabetes get in their way. Go to http://www.biosolutionscorp.lockerdome.com for more details.
Catalyst Pharmaceutical Partners, Inc. (CPRX), a specialty pharmaceutical company focused on the development and commercialization of novel prescription drugs targeting rare (orphan) neuromuscular and neurological diseases, today announced that its investigational product Firdapse(TM) (amifampridine phosphate) has received "Breakthrough Therapy Designation" by the U.S. Food and Drug Administration (FDA) for the symptomatic treatment of patients with Lambert-Eaton Myasthenic Syndrome (LEMS). Firdapse(TM) is Catalyst's investigational therapy that is being evaluated for the treatment of the debilitating symptoms associated with LEMS, including muscle weakness.
MannKind Corporation (MNKD), a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic products for diabetes and cancer in the United States. Its lead product candidate includes AFREZZA inhalation powder, an insulin that is in late-stage clinical investigation for the treatment of adults with type 1 or type 2 diabetes for the control of hyperglycemia. MNKD closed up 2.4% on above average trading volume of 12.9Million shares on Tuesday August 27, 2013.
Amgen (AMGN) announced that it will present new data on omecamtiv mecarbil, a small molecule cardiac myosin activator that is being studied for the treatment of heart failure in collaboration with Cytokinetics. Amgen will also present data on AMG 145, an investigational human monoclonal antibody that inhibits PCSK9, a protein that reduces the liver's ability to remove low-density lipoprotein cholesterol (LDL-C), or "bad" cholesterol, from the blood.1 Amgen will present the data at the upcoming ESC Congress 2013, organized by the European Society of Cardiology, in Amsterdam.
Accuray Incorporated (ARAY) announced financial results for the fourth quarter and fiscal year ended June 30, 2013. Non-GAAP results are provided to enhance understanding of Accuray's ongoing core results of operations. Accuray announced continued strength in new orders booked in the fourth quarter and first patients treated in the United States with the new CyberKnife(r) M6(TM) and TomoTherapy(r) H(TM) Series Systems as well as continued financial discipline, operating expense control and decreased operating losses. Read the full 4th Qtr results at http://finance.yahoo.com/news/accuray-announces-results-fourth-quarter-202400364.html.
FinancialNewsMedia.com is leading provider of third party publishing & news dissemination services. If you would like more information regarding our news coverage solutions, please visit http://www.financialnewsmedia.com for more details. Get an edge on the market with our Premium News Alerts that are FREE for a limited time at http://www.financialnewsmedia.com/. Follow us on Facebook: http://www.facebook.com/financialnewsmedia and Twitter: http://twitter.com/FNMgroup. Sign up for our FREE SMS News alerts delivered directly to your mobile phone by texting the word PRESS to 545454. (SMS alerts are free, however data rates may apply, check your wireless plan for details.)
DISCLAIMER: FN Media Group LLC (FNMG) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNMG is NOT affiliated in any manner with any company mentioned herein. FNMG and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNMG's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. The companies that are discussed in this release may or may not have approved the statements made in this release. FNMG is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks.
FNMG HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements.
SOURCE FN Media Group LLC